Abbott added another successful year to the books, beating analyst estimates as the company played a key role in supporting important health needs for customers and patients across the world throughout 2021. Contributing to this success was excellent fourth-quarter performance — including strong organic sales — and growth across all four key business areas for the quarter and full year, reinforcing the strength and resilience of the company's diversified model. Here are the key numbers. For the quarter: $11.5 billion in worldwide sales, up 7.7% organic* (7.2% reported) versus the fourth quarter of 2020. For the full year: $43.1 billion in worldwide sales, up 22.9% organic (24.5% reported). $5.21 adjusted diluted earnings per share (EPS) from continuing operations, reflecting 42.7% growth versus the prior year.1 Abbott issued full-year guidance for 2022 adjusted diluted EPS from continuing operations of at least $4.70.2 This guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion, which Abbott expects to occur early in the year and will update on a quarterly basis. These are the key fourth-quarter highlights: Double digit growth in Medical Devices — up 15.9% organic (15.1% reported) — driven by continued recovery from the COVID-19 pandemic and strong Diabetes Care growth. Sales of FreeStyle Libre systems were $1 billion, which translates to an increase of 36% organic (35.4% reported). Solid Diagnostics sales — up 3.3% organic (2.9% reported) — reflects continued strong demand for COVID-19 tests, similar to fourth-quarter 2020. Since the start of the pandemic, Abbott distributed more than 1.4 billion COVID-19 tests around the world. Excluding COVID-19 testing-related sales, global Diagnostics sales for the quarter increased 8.7% organic (8.2% reported).3 Strong Nutrition performance — up 5.9% organic (5.5% reported) — spurred by international adult and U.S. pediatric Nutrition, with strong performance of Abbott's market-leading brands Ensure, Glucerna and Pedialyte. New product approvals and launches across Abbott in 2021 continue to bolster the company's product pipeline. Significant gains were made in Structural Heart with Abbott receiving FDA approval of two key minimally invasive devices — Amplatzer Amulet Left Atrial Appendage Occluder and Portico with FlexNav transcatheter aortic valve implantation/replacement (TAVI/TAVR) system — and CE Mark for Navitor, its latest-generation TAVI/TAVR system. Abbott also received FDA approval of its Neurosphere Virtual Clinic — a first-of-its-kind remote neuromodulation patient-care tech in the U.S. — and expanded Medicare reimbursement for MitraClip. For full financials and reconciliation of non-GAAP measures, you can read Abbott's press release. For further information, take a look at some additional materials below: Abbott Chairman and CEO Robert Ford summarizes the company's performance and pipeline advancements in 2021.